---

Highlights of April 2023

 

1.      Cash rich Serum Institute of India to double investment in Biocon's unit to INR 2,455 crore (~US$300 million).

2.      Ipca Labs to acquire 33.4% stake in Unichem Labs for INR 1,034 crore (~USD 130 million).

3.      CCI clears Berhyanda's acquisition of up to 76.10% in India based Suven Pharma.

4.      India based Redcliffe Labs buys integrated diagnostics chain Medicentre Sonography & Clinical Lab.

5.      SRL Diagnostic completes acquisition of Lifeline Laboratory.

6.      Eli Lilly to sell low blood sugar drug to Amphastar who will pay US$500 million at closing and another US$125 million in cash after one year.

7.      4DMT to acquire Aevitas asset for up to US$140 million.

8.      Partners Xbrane and STADA to supply Ximluci (ranibizumab biosimilar) in England via a National Health Service (NHS) Framework Agreement.

9.      Aspect Biosystems and Novo Nordisk have announced a collaboration with the goal of delivering a new class of truly disease-modifying treatments for diabetes and obesity.

10.  Devyser and Thermo Fisher Scientific have signed a collaboration and distribution agreement that gives Thermo Fisher exclusive rights to commercialize, under combined brands, Devyser’s post-transplant portfolio of NGS products in North America and Europe.

11.  Genmab and Argenx have entered into a collaboration agreement to jointly discover, develop, and commercialize novel therapeutic antibodies with applications in immunology, as well as in oncology therapeutic areas.

12.  Aspect Biosystems and Novo Nordisk enter partnership to develop bio-printed tissue therapeutics.

Highlights at Aagami:

1.      Aagami is attending BIO International Convention 2023 (June 5-8) and accepting meetings on the BIO one-on-one partnering system. Please send your meeting requests soon as the calendar is filling up.

2.      New Client Win: Award-winning New York biotech specializing in molecular engineering, RNAi and CRISPR/Cas9 technologies.

3.      New Client Win: South Korean Innovator of the world’s first digital monitoring and management solution for Thyroid Dysfunction & Complications.

4.      Aagami CEO Dinesh Jain hosted an event at MIHQ (Michigan Innovation Headquarters) in Ann Arbor on April 27^th.

INFOCUS: Select opportunities available:

For Partnering/Licensing/ Investment:

1. Licensing/Co-development: Easy to apply world’s First Transdermal Tizanidine Patch for the Management of Spasticity. Impressive Phase 1 results. Ready to initiate Phase 2.
2.       Lidocaine 10% Topical Patch; NDA approval expected in Q4 of 2023. (Licensing for US available). Made using Proprietary drug formulation technology, ILTS® (Ionic Liquid Transdermal Technology). Indication: the treatment of PHN (postherpetic neuralgia)
3. Midwest US based Pharma’s Phase 2 stage First-in-Class Non-Opioid Analgesic for both chronic and acute Pain Relief – Seeking funding/licensing/co-development partnerships.
4. A single (monovalent) vaccine for Targeting Salmonella, ETEC / E. coli, Campylobacter, Shigella. Fulfills an unmet need for treating Bacterial Dysentery. Seeking funding/licensing/co-development partnerships.
5. $40 Million Series C: On the market, US FDA approved novel portable MRI Guided Treatment, Diagnosis and Screening, for Urology applications. California based client.
6. Seeking Investment: Precision fermentation-based technology to produce Natural Soluble Melanin at a cost hundreds of times lower. The current round proceeds will be used to achieve milestone of making a market ready Sunscreen cream using Melanin, under Consumer Health & Wellness category.

For Acquisition:

1.      Available at a very reasonable price Mountain View Pharma (MVP) including its PharmaPEG® technology, product candidates, data package of ~20 drug candidates, IP etc.- for Next-generation biologics and substantial returns.